Vaginal estrogens

Vaginal estrogen

What is Ovestin (vaginal estrogen cream)?

Ovestin is an estrogen cream. Unlike systemic MHT (patches, gels, or pills), it acts locally around the vagina and vulva. The estrogen it contains is estriol, a weak body-identical - meaning it’s the same as the estrogen naturally produced in the body.

You can also get Vagifem, this isn't funded in NZ, but it contains estradiol.







Why might we need it?

Vaginal estrogen creams help protect the vaginal and vulval skin, reduce inflammation, and prevent thinning or atrophy.

Around 80% of women are affected by genitourinary syndrome of menopause (GSM).

Symptoms can include:

  • Itching or dryness
  • Skin inflammation (dermatitis)
  • Pain during sex
  • Recurrent vaginal or urinary infections
  • Changes in discharge or smell
  • Problems passing urine
  • Urinary urgency

These symptoms often worsen over time, so starting treatment early is beneficial. Vaginal symptoms are very common after menopause, but they can also appear earlier and are often under-recognised.







Possible risks with using Ovestin cream

The estrogen in Ovestin cream works only locally, so it does not carry the same risks as systemic MHT. There’s no known increased risk of breast or uterine cancer.




Possible side effects of Ovestin

Most women tolerate Ovestin well. Because the estrogen works locally, side effects are usually mild and temporary. Common ones include:

  • Mild vaginal irritation or itching when first starting
  • Stinging or burning after application (often improves within a couple of weeks)
  • Increased vaginal discharge
  • Breast tenderness (rare, usually if also on systemic estrogen)

Serious side effects are very rare, but if you notice persistent pain, unusual bleeding, or any concerning symptoms, see your doctor.




⏰ Starting Ovestin cream

  • Begin with daily use for 2–3 weeks.
  • Then reduce to twice a week for maintenance.
  • Some women need more frequent use from time to time.
  • About 50% of women already using systemic MHT don’t need extra vaginal estrogen.
  • Symptoms may improve once estrogen patches reach therapeutic levels.
  • Mild stinging at first is common and usually settles within a couple of weeks.


❓Using the applicator or your finger

Some women find the applicator can be uncomfortable or tricky to clean. An alternative is to measure a dose onto your finger and apply it internally or externally where needed.

  • Cream works best when applied high in the vagina (front wall).
  • Once you’re confident with the dose amount, you can use your finger instead of the applicator.







FAQs about using Ovestin

💬 What if I have my period when using Ovestin?
You can skip doses during your period, or just apply it externally if more comfortable.

💬 Can I have sex after using it?
It’s not ideal to have sex immediately after applying Ovestin, wait a few hours if possible.

💬 What if I do have sex after applying it?
Absorption through penile skin is minimal, so there’s no need to worry, but best not to make it a regular habit.

💬 Can I use it on my face or elsewhere?
Not recommended. Ovestin contains chlorhexidine, a preservative better suited to internal application. Ovestin is only indicated for use around the vulva and vagina.

💬 What if I feel embarrassed asking for it?
You’re not alone, these symptoms are common and very real. You can write a note, ask a pharmacist, or bring a prepared question to your doctor.

💬 Will I need it forever?
Possibly. Symptoms often return when treatment stops. Think of it like a skin cream - ongoing dryness may need ongoing support.

💬 Can Ovestin cause thrush?
Sometimes. But don’t assume - it could be irritation or another cause. Always get it checked by your doctor before treating yourself.

💬 I’m on the pill but still have vaginal dryness - is that possible?
Yes. Some combined oral contraceptives can lower local estrogen and even shrink the labia minora mildly, causing dryness or discomfort.

💬 What else can I use?

  • Moisturisers for long-term hydration
  • Lubricants for comfort during sex or intimacy

💬 Will I still need lubricant if I’m using Ovestin?
Maybe. Using a lubricant doesn’t mean Ovestin isn’t working. It’s simply an extra tool many people still find helpful.

Take-home points:

  • Around half of women on systemic MHT don’t need extra vaginal estrogen, but for those who still have local symptoms, adding it is safe and effective.
  • Low-dose vaginal estrogen doesn’t require progesterone, as it doesn’t raise body-wide hormone levels or affect the endometrium.
  • Systemic symptoms may be experience at initial use due to thinner skin, but over 2-3 weeks there is minimal systemic absorption.
We have a course on vaginal estrogen coming soon!


** Sexual Relations and Comfort

When discussing sexual relations, it’s important to note this includes any form of sexual activity - whether partnered or solo, external or penetrative, and may involve digital or vibrator stimulation. The goal of treatment is to restore comfort, confidence, and wellbeing, not to assume a specific sexual context.

Nick Panay, Seng Bin Ang, Rebecca Cheshire, Steven R. Goldstein, Pauline Maki, Rossella E. Nappi & on behalf of the International Menopause Society Board (13 Sep 2024): Menopause and MHT in 2024: addressing the key controversies – an International Menopause Society White Paper, Climacteric, DOI: 10.1080/13697137.2024.2394950 | Link
The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020 Sep;27(9):976-992. doi: 10.1097/GME.0000000000001609. PMID: 32852449. | Link
Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause. 2014 Oct;21(10):1063-8. doi: 10.1097/GME.0000000000000329. PMID: 25160739. | Link
“The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022 Jul 1;29(7):767-794. doi: 10.1097/GME.0000000000002028. PMID: 35797481. | Link
ï»żSanten RJ. Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric. 2015 Apr;18(2):121-34. doi: 10.3109/13697137.2014.947254. Epub 2014 Oct 18. PMID: 25327484. | Link
Santen RJ, Mirkin S, Bernick B, Constantine GD. Systemic estradiol levels with low-dose vaginal estrogens. Menopause. 2020 Mar;27(3):361-370. doi: 10.1097/GME.0000000000001463. PMID: 31794498; PMCID: PMC7050796. | Link
Labrie F, Cusan L, Gomez JL, CÎté I, Bérubé R, Bélanger P, Martel C, Labrie C. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause. 2009 Jan-Feb;16(1):30-6. doi: 10.1097/gme.0b013e31817b6132. PMID: 18820592. | Link
Moegele M, Buchholz S, Seitz S, Ortmann O. Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors. Arch Gynecol Obstet. 2012 May;285(5):1397-402. doi: 10.1007/s00404-011-2181-6. Epub 2012 Jan 3. PMID: 22212649. | Link

Complete and Continue  
Discussion

0 comments